James Totterdell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Totterdell has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Laurence Snelling
Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
8 shared publications - Gladymar Pérez Chacón
Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia
6 shared publications - Marie J. Estcourt
Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
6 shared publications - Peter Richmond
Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Western Australia, Australia
6 shared publications - Mark Jones
Hunter Medical Research Institute, Newcastle, Australia
5 shared publications - Claire S. Waddington
Liverpool School Tropical Medicine, Liverpool, United Kingdom
4 shared publications
Latest Publications
- Open Access
Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial
Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old (‘aP-only&rsquo schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old (‘mixed wP/aP&rsquo schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome. Results A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP/aP schedule compared to recipients of the aP-only schedule was 0.01 (-0.02, 0.04; probability [Conclusions There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p. Clinical implications An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants. Capsule summary An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants. Key words Diphtheria-Tetanus-Pertussis Vaccine. Diphtheria-Tetanus-acellular Pertussis Vaccines. Food Hypersensitivity. Infant. Australia.
Open AccessEfficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial
Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old (‘aP-only&rsquo schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old (‘mixed wP/aP&rsquo schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome. Results A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP/aP schedule compared to recipients of the aP-only schedule was 0.01 (-0.02, 0.04; probability [Conclusions There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p. Clinical implications An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants. Capsule summary An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants. Key words Diphtheria-Tetanus-Pertussis Vaccine. Diphtheria-Tetanus-acellular Pertussis Vaccines. Food Hypersensitivity. Infant. Australia.
- Open Access
- 8 September 2026
- Published by Wiley in Journal of Paediatrics and Child Health
FOSUTI : Fosfomycin Versus Standard of Care to Treat Children With Urinary Tract Infections
- 8 September 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Open AccessFOSUTI : Fosfomycin Versus Standard of Care to Treat Children With Urinary Tract Infections
- Open Access
- 23 May 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (1) , 106515
Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines
- 23 May 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (1) , 106515
Open AccessImmune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines
- Open Access
Immunogenicity of co-administered vaccine antigens with whole-cell or acellular pertussis vaccines in infancy: a randomised controlled trial
Summary: Background: Whole-cell pertussis (wP) and acellular pertussis (aP) vaccines evoke different immune responses to pertussis vaccine antigens. We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers. Methods: We randomised Australian infants in a 1:1 ratio to receive either a mixed wP/aP schedule (pentavalent diphtheria-tetanus-wP-hepatitis B- Haemophilus influenzae type b; DTwP-HepB-Hib vaccine at 6 weeks old followed by hexavalent DTaP-inactivated poliovirus vaccine (IPV)-HepB-Hib vaccine at 4 and 6 months old) or to aP-only priming doses of hexavalent DTaP-IPV-HepB-Hib vaccine at the same ages. All infants received 13-valent pneumococcal conjugate vaccine (13vPCV) at 6 weeks, 4 and 12 months of age and DTaP-IPV and Hib vaccine boosters at 18 months. We estimated the ratio (GMR) of IgG geometric mean concentrations (GMCs) in the wP/aP and aP-only groups for the serotypes included in the 13vPCV, for Hib capsular polysaccharide polyribosylribitol phosphate (PRP), and for hepatitis B surface antigen (HBsAg) at 6, 7, 18, and 19 months. We assessed whether the wP/aP schedule is non-inferior to the aP-only schedule for co-administered vaccine antigens (GMR>2/3). Trial registration: ACTRN12617000065392p. Results: Between March 2018 and January 2020, 150 infants were randomised (75 per study arm). Responses to all 13vPCV serotypes and Hib-PRP at 6, 7, 18, and 19 months old, as well as HBsAg at 6 and 7 months old were non-inferior (>90% probability). Sera GMCs were higher for each 13vPCV serotype, Hib-PRP, and HBsAg at each timepoint in the wP/aP group than in the aP-only group. Interpretation: A mixed wP/aP schedule resulted in non-inferior IgG responses to co-administered vaccine antigens compared to the standard aP-only schedule for pertussis primary immunisation. Funding: Telethon New Children’s Hospital Research Fund and National Health and Medical Research Council. Research in context: Evidence before this study: Combination vaccines incorporate antigens that protect against multiple diseases into a single injection. Most low- and middle-income countries (LMICs) currently use wP combination vaccines. Due to the need for periodic boosters to protect older children, adolescents, and adults, these countries may consider moving to the less reactogenic aP combination vaccines that are routinely used in most high-income countries. We searched for evidence about whether a mixed wP/aP primary schedule impacts the immunogenicity of co-administered vaccines. We were particularly interested in evidence for impacts on 13vPCV 2 + 1 schedule and other pneumococcal dose-sparing schedules. We searched PubMed on May 23, 2024, for randomised controlled trials using the following search terms “pneumococcal”, “routine vaccin*”, and “pertussis” combined with Boolean operators, without date or language restrictions. We failed to identify any head-to-head randomised comparisons of the effect of heterologous (mixed) versus homologous pertussis vaccine primary series on co-administered vaccine antigens. Our previous meta-analysis reviewed 15 randomised controlled studies that compared serious adverse events among infants receiving wP versus aP as a first dose before 6 months of age. Few studies reported immune responses to non-DTP co-administered antigens. These findings suggest enhanced Hib responses among recipients of a three-dose primary series of wP compared to those who received three primary aP doses, non-inferior Hib-PRP seroprotection among aP compared to wP vaccinees, and mixed results regarding HBsAg-IgG levels post-wP priming. Both wP and aP groups exhibited weaker Hib-PRP IgG responses when DTP-Hib vaccines were co-administered with meningococcal serogroup C vaccine conjugated to cross-reactive material 197 (CRM 197 ) compared to the meningococcal serogroup C vaccine conjugated to tetanus toxoid (TT). Added value of this study: This paper is the first reported evidence of a mixed wP/aP schedule resulting in non-inferior IgG responses to co-administered vaccine antigens compared to the standard homologous aP-only schedule for pertussis primary immunisation. In addition, enhanced immune responses were observed to all serotypes included in the 13vPCV and Hib-PRP vaccines in children receiving the mixed wP/aP vaccination strategy versus those vaccinated with a standard aP-only schedule. Implications of all the available evidence: In settings transitioning from using wP to aP multi-component vaccines, infants receiving a mixed schedule (with wP as the first dose) can be expected have non-inferior, and possibly superior, antibody responses to concomitant vaccine antigens. To better understand the underlying mechanisms of our findings, the assessment of opsonophagocytic activity response rates and serotype-specific memory B cell immune responses to PCV antigens is required. Large population-based studies, particularly in countries where pneumococcal and Hib disease burdens remain high, should be conducted to determine if the observed effects on immune responses translate into differences in protection against disease.
Open AccessImmunogenicity of co-administered vaccine antigens with whole-cell or acellular pertussis vaccines in infancy: a randomised controlled trial
Summary: Background: Whole-cell pertussis (wP) and acellular pertussis (aP) vaccines evoke different immune responses to pertussis vaccine antigens. We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers. Methods: We randomised Australian infants in a 1:1 ratio to receive either a mixed wP/aP schedule (pentavalent diphtheria-tetanus-wP-hepatitis B- Haemophilus influenzae type b; DTwP-HepB-Hib vaccine at 6 weeks old followed by hexavalent DTaP-inactivated poliovirus vaccine (IPV)-HepB-Hib vaccine at 4 and 6 months old) or to aP-only priming doses of hexavalent DTaP-IPV-HepB-Hib vaccine at the same ages. All infants received 13-valent pneumococcal conjugate vaccine (13vPCV) at 6 weeks, 4 and 12 months of age and DTaP-IPV and Hib vaccine boosters at 18 months. We estimated the ratio (GMR) of IgG geometric mean concentrations (GMCs) in the wP/aP and aP-only groups for the serotypes included in the 13vPCV, for Hib capsular polysaccharide polyribosylribitol phosphate (PRP), and for hepatitis B surface antigen (HBsAg) at 6, 7, 18, and 19 months. We assessed whether the wP/aP schedule is non-inferior to the aP-only schedule for co-administered vaccine antigens (GMR>2/3). Trial registration: ACTRN12617000065392p. Results: Between March 2018 and January 2020, 150 infants were randomised (75 per study arm). Responses to all 13vPCV serotypes and Hib-PRP at 6, 7, 18, and 19 months old, as well as HBsAg at 6 and 7 months old were non-inferior (>90% probability). Sera GMCs were higher for each 13vPCV serotype, Hib-PRP, and HBsAg at each timepoint in the wP/aP group than in the aP-only group. Interpretation: A mixed wP/aP schedule resulted in non-inferior IgG responses to co-administered vaccine antigens compared to the standard aP-only schedule for pertussis primary immunisation. Funding: Telethon New Children’s Hospital Research Fund and National Health and Medical Research Council. Research in context: Evidence before this study: Combination vaccines incorporate antigens that protect against multiple diseases into a single injection. Most low- and middle-income countries (LMICs) currently use wP combination vaccines. Due to the need for periodic boosters to protect older children, adolescents, and adults, these countries may consider moving to the less reactogenic aP combination vaccines that are routinely used in most high-income countries. We searched for evidence about whether a mixed wP/aP primary schedule impacts the immunogenicity of co-administered vaccines. We were particularly interested in evidence for impacts on 13vPCV 2 + 1 schedule and other pneumococcal dose-sparing schedules. We searched PubMed on May 23, 2024, for randomised controlled trials using the following search terms “pneumococcal”, “routine vaccin*”, and “pertussis” combined with Boolean operators, without date or language restrictions. We failed to identify any head-to-head randomised comparisons of the effect of heterologous (mixed) versus homologous pertussis vaccine primary series on co-administered vaccine antigens. Our previous meta-analysis reviewed 15 randomised controlled studies that compared serious adverse events among infants receiving wP versus aP as a first dose before 6 months of age. Few studies reported immune responses to non-DTP co-administered antigens. These findings suggest enhanced Hib responses among recipients of a three-dose primary series of wP compared to those who received three primary aP doses, non-inferior Hib-PRP seroprotection among aP compared to wP vaccinees, and mixed results regarding HBsAg-IgG levels post-wP priming. Both wP and aP groups exhibited weaker Hib-PRP IgG responses when DTP-Hib vaccines were co-administered with meningococcal serogroup C vaccine conjugated to cross-reactive material 197 (CRM 197 ) compared to the meningococcal serogroup C vaccine conjugated to tetanus toxoid (TT). Added value of this study: This paper is the first reported evidence of a mixed wP/aP schedule resulting in non-inferior IgG responses to co-administered vaccine antigens compared to the standard homologous aP-only schedule for pertussis primary immunisation. In addition, enhanced immune responses were observed to all serotypes included in the 13vPCV and Hib-PRP vaccines in children receiving the mixed wP/aP vaccination strategy versus those vaccinated with a standard aP-only schedule. Implications of all the available evidence: In settings transitioning from using wP to aP multi-component vaccines, infants receiving a mixed schedule (with wP as the first dose) can be expected have non-inferior, and possibly superior, antibody responses to concomitant vaccine antigens. To better understand the underlying mechanisms of our findings, the assessment of opsonophagocytic activity response rates and serotype-specific memory B cell immune responses to PCV antigens is required. Large population-based studies, particularly in countries where pneumococcal and Hib disease burdens remain high, should be conducted to determine if the observed effects on immune responses translate into differences in protection against disease.
- Open Access
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): Statistical analysis plan
A bstract: The MOTIVATE-C study explores a critical question in hepatitis C treatment: How do financial incentives influence patients’ decisions to initiate direct-acting antiviral (DAA) therapy? Using an innovative Bayesian adaptive design, the research aims to determine the precise relationship between monetary support and treatment initiation among individuals with untreated hepatitis C virus. The study’s unique approach involves response-adaptive randomization, which dynamically allocates participants to different financial incentive levels. As the trial progresses, doses more likely to encourage treatment will receive increased emphasis, while less effective incentive levels may be systematically eliminated through pre-defined futility stopping rules. Participants will be tracked for DAA therapy initiation within 12 weeks of enrollment, with dedicated study navigators assisting them through the treatment access process. The primary analysis will adhere to the intention-to-treat principle, ensuring a comprehensive and unbiased evaluation of the intervention’s effectiveness. This manuscript details the statistical analysis plan, presenting the precise methodological framework, decision-making criteria, and analytical thresholds that will guide the study’s interpretation of how financial incentives might overcome barriers to hepatitis C treatment.
Open AccessFinancial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): Statistical analysis plan
A bstract: The MOTIVATE-C study explores a critical question in hepatitis C treatment: How do financial incentives influence patients’ decisions to initiate direct-acting antiviral (DAA) therapy? Using an innovative Bayesian adaptive design, the research aims to determine the precise relationship between monetary support and treatment initiation among individuals with untreated hepatitis C virus. The study’s unique approach involves response-adaptive randomization, which dynamically allocates participants to different financial incentive levels. As the trial progresses, doses more likely to encourage treatment will receive increased emphasis, while less effective incentive levels may be systematically eliminated through pre-defined futility stopping rules. Participants will be tracked for DAA therapy initiation within 12 weeks of enrollment, with dedicated study navigators assisting them through the treatment access process. The primary analysis will adhere to the intention-to-treat principle, ensuring a comprehensive and unbiased evaluation of the intervention’s effectiveness. This manuscript details the statistical analysis plan, presenting the precise methodological framework, decision-making criteria, and analytical thresholds that will guide the study’s interpretation of how financial incentives might overcome barriers to hepatitis C treatment.
- Open Access
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals in India. Participants Adults Intervention DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days. Main outcome measures The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis. Results Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults Conclusion Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19. Trial registration number ClinicalTrials.gov NCT05122182.
Open AccessCombination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial
Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19. Design Prospective, multicentre, double-blind, placebo-controlled trial. Setting Ten acute care hospitals in India. Participants Adults Intervention DMX-200 120 mg two times per day, or placebo, on background of titratable candesartan commencing at 4 mg two times per day, for 28 days. Main outcome measures The primary endpoint was COVID-19 disease severity on a modified WHO Clinical Progression Scale (WHO scale) on day 14. Secondary outcomes included the WHO scale at days 28, 60, 90 and 180; intensive care unit (ICU) admission, respiratory failure or death within 28 days; length of hospitalisation; and requirement for ventilatory support or dialysis. Results Between December 2021 and August 2022, 518 people were screened, with 49 randomised to DMX-200 or placebo on a background of candesartan. The study was terminated early due to recruitment barriers, including an external requirement to restrict enrolment to adults Conclusion Due to recruitment barriers, the study was unable to determine whether DMX-200 improves clinical outcomes in people with COVID-19. Trial registration number ClinicalTrials.gov NCT05122182.
- Open Access
- 17 June 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-14
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study
Background: Untreated hepatitis C virus (HCV) infection can result in cirrhosis and hepatocellular cancer. Direct-acting antiviral (DAA) therapies are highly effective and have few side effects compared to older interferon-based therapy. Despite the Australian government providing subsidised and unrestricted access to DAA therapy for chronic HCV infection, uptake has not been sufficient to meet the global target of eliminating HCV as a public health threat by 2030. This study will offer people with HCV financial incentives of varying values in order to evaluate its effect on initiation of DAA therapy in primary care.Methods: Australian adults (18 years or older) who self-report as having current untreated HCV infection can register to participate via an automated SMS-based system. Following self-screening for eligibility, registrants are offered a financial incentive of randomised value (AUD 0 to 1000) to initiate DAA therapy. Study treatment navigators contact registrants who have consented to be contacted, to complete eligibility assessment, outline the study procedures (including the requirement for participants to consult a primary care provider), obtain consent, and finalise enrolment. Enrolled participants receive their offered incentive on provision of evidence of DAA therapy initiation within 12 weeks of registration (primary endpoint). Balanced randomisation is used across the incentive range until the first analysis, after which response-adaptive randomisation will be used to update the assignment probabilities. For the primary analysis, a Bayesian 4-parameter EMAX model will be used to estimate the dose–response curve and contrast treatment initiation at each incentive value against the control arm (AUD 0). Specified secondary statistical and economic analyses will evaluate the effect of incentives on adherence to DAA therapy, virological response, and cost-effectiveness.Discussion: This project seeks to gain an understanding of the dose–response relationship between incentive value and DAA treatment initiation, while maximising the number of people treated for HCV within fixed budget and time constraints. In doing so, we hope to offer policy-relevant recommendation(s) for the use of financial incentives as a pragmatic, efficient, and cost-effective approach to achieving elimination of HCV from Australia.Trial registration: ANZCTR (anzctr.org.au), Identifier ACTRN12623000024640, Registered 11 January 2023 (https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384923&isReview=true).
- 17 June 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-14
Open AccessFinancial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study
Background: Untreated hepatitis C virus (HCV) infection can result in cirrhosis and hepatocellular cancer. Direct-acting antiviral (DAA) therapies are highly effective and have few side effects compared to older interferon-based therapy. Despite the Australian government providing subsidised and unrestricted access to DAA therapy for chronic HCV infection, uptake has not been sufficient to meet the global target of eliminating HCV as a public health threat by 2030. This study will offer people with HCV financial incentives of varying values in order to evaluate its effect on initiation of DAA therapy in primary care.Methods: Australian adults (18 years or older) who self-report as having current untreated HCV infection can register to participate via an automated SMS-based system. Following self-screening for eligibility, registrants are offered a financial incentive of randomised value (AUD 0 to 1000) to initiate DAA therapy. Study treatment navigators contact registrants who have consented to be contacted, to complete eligibility assessment, outline the study procedures (including the requirement for participants to consult a primary care provider), obtain consent, and finalise enrolment. Enrolled participants receive their offered incentive on provision of evidence of DAA therapy initiation within 12 weeks of registration (primary endpoint). Balanced randomisation is used across the incentive range until the first analysis, after which response-adaptive randomisation will be used to update the assignment probabilities. For the primary analysis, a Bayesian 4-parameter EMAX model will be used to estimate the dose–response curve and contrast treatment initiation at each incentive value against the control arm (AUD 0). Specified secondary statistical and economic analyses will evaluate the effect of incentives on adherence to DAA therapy, virological response, and cost-effectiveness.Discussion: This project seeks to gain an understanding of the dose–response relationship between incentive value and DAA treatment initiation, while maximising the number of people treated for HCV within fixed budget and time constraints. In doing so, we hope to offer policy-relevant recommendation(s) for the use of financial incentives as a pragmatic, efficient, and cost-effective approach to achieving elimination of HCV from Australia.Trial registration: ANZCTR (anzctr.org.au), Identifier ACTRN12623000024640, Registered 11 January 2023 (https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384923&isReview=true).
- Open Access
- 10 June 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (6) , e1004414
Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial
Background: In many countries, infant vaccination with acellular pertussis (aP) vaccines has replaced use of more reactogenic whole-cell pertussis (wP) vaccines. Based on immunological and epidemiological evidence, we hypothesised that substituting the first aP dose in the routine vaccination schedule with wP vaccine might protect against IgE-mediated food allergy. We aimed to compare reactogenicity, immunogenicity, and IgE-mediated responses of a mixed wP/aP primary schedule versus the standard aP-only schedule. Methods and findings: OPTIMUM is a Bayesian, 2-stage, double-blind, randomised trial. In stage one, infants were assigned (1:1) to either a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB, Pentabio PT Bio Farma, Indonesia) or a hexavalent aP vaccine (DTaP-Hib-HepB-IPV, Infanrix hexa, GlaxoSmithKline, Australia) at approximately 6 weeks old. Subsequently, all infants received the hexavalent aP vaccine at 4 and 6 months old as well as an aP vaccine at 18 months old (DTaP-IPV, Infanrix-IPV, GlaxoSmithKline, Australia). Stage two is ongoing and follows the above randomisation strategy and vaccination schedule. Ahead of ascertainment of the primary clinical outcome of allergist-confirmed IgE-mediated food allergy by 12 months old, here we present the results of secondary immunogenicity, reactogenicity, tetanus toxoid IgE-mediated immune responses, and parental acceptability endpoints. Serum IgG responses to diphtheria, tetanus, and pertussis antigens were measured using a multiplex fluorescent bead-based immunoassay; total and specific IgE were measured in plasma by means of the ImmunoCAP assay (Thermo Fisher Scientific). The immunogenicity of the mixed schedule was defined as being noninferior to that of the aP-only schedule using a noninferiority margin of 2/3 on the ratio of the geometric mean concentrations (GMR) of pertussis toxin (PT)-IgG 1 month after the 6-month aP. Solicited adverse reactions were summarised by study arm and included all children who received the first dose of either wP or aP. Parental acceptance was assessed using a 5-point Likert scale. The primary analyses were based on intention-to-treat (ITT); secondary per-protocol (PP) analyses were also performed. The trial is registered with ANZCTR (ACTRN12617000065392p). Between March 7, 2018 and January 13, 2020, 150 infants were randomised (75 per arm). PT-IgG responses of the mixed schedule were noninferior to the aP-only schedule at approximately 1 month after the 6-month aP dose [GMR = 0·98, 95% credible interval (0·77 to 1·26); probability (GMR > 2/3) > 0·99; ITT analysis]. At 7 months old, the posterior median probability of quantitation for tetanus toxoid IgE was 0·22 (95% credible interval 0·12 to 0·34) in both the mixed schedule group and in the aP-only group. Despite exclusions, the results were consistent in the PP analysis. At 6 weeks old, irritability was the most common systemic solicited reaction reported in wP (65 [88%] of 74) versus aP (59 [82%] of 72) vaccinees. At the same age, severe systemic reactions were reported among 14 (19%) of 74 infants after wP and 8 (11%) of 72 infants after aP. There were 7 SAEs among 5 participants within the first 6 months of follow-up; on blinded assessment, none were deemed to be related to the study vaccines. Parental acceptance of mixed and aP-only schedules was high (71 [97%] of 73 versus 69 [96%] of 72 would agree to have the same schedule again). Conclusions: Compared to the aP-only schedule, the mixed schedule evoked noninferior PT-IgG responses, was associated with more severe reactions, but was well accepted by parents. Tetanus toxoid IgE responses did not differ across the study groups. Trial registration: Trial registered at the Australian and New Zealand Clinical 207 Trial Registry (ACTRN12617000065392p).
- 10 June 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (6) , e1004414
Open AccessImmunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial
Background: In many countries, infant vaccination with acellular pertussis (aP) vaccines has replaced use of more reactogenic whole-cell pertussis (wP) vaccines. Based on immunological and epidemiological evidence, we hypothesised that substituting the first aP dose in the routine vaccination schedule with wP vaccine might protect against IgE-mediated food allergy. We aimed to compare reactogenicity, immunogenicity, and IgE-mediated responses of a mixed wP/aP primary schedule versus the standard aP-only schedule. Methods and findings: OPTIMUM is a Bayesian, 2-stage, double-blind, randomised trial. In stage one, infants were assigned (1:1) to either a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB, Pentabio PT Bio Farma, Indonesia) or a hexavalent aP vaccine (DTaP-Hib-HepB-IPV, Infanrix hexa, GlaxoSmithKline, Australia) at approximately 6 weeks old. Subsequently, all infants received the hexavalent aP vaccine at 4 and 6 months old as well as an aP vaccine at 18 months old (DTaP-IPV, Infanrix-IPV, GlaxoSmithKline, Australia). Stage two is ongoing and follows the above randomisation strategy and vaccination schedule. Ahead of ascertainment of the primary clinical outcome of allergist-confirmed IgE-mediated food allergy by 12 months old, here we present the results of secondary immunogenicity, reactogenicity, tetanus toxoid IgE-mediated immune responses, and parental acceptability endpoints. Serum IgG responses to diphtheria, tetanus, and pertussis antigens were measured using a multiplex fluorescent bead-based immunoassay; total and specific IgE were measured in plasma by means of the ImmunoCAP assay (Thermo Fisher Scientific). The immunogenicity of the mixed schedule was defined as being noninferior to that of the aP-only schedule using a noninferiority margin of 2/3 on the ratio of the geometric mean concentrations (GMR) of pertussis toxin (PT)-IgG 1 month after the 6-month aP. Solicited adverse reactions were summarised by study arm and included all children who received the first dose of either wP or aP. Parental acceptance was assessed using a 5-point Likert scale. The primary analyses were based on intention-to-treat (ITT); secondary per-protocol (PP) analyses were also performed. The trial is registered with ANZCTR (ACTRN12617000065392p). Between March 7, 2018 and January 13, 2020, 150 infants were randomised (75 per arm). PT-IgG responses of the mixed schedule were noninferior to the aP-only schedule at approximately 1 month after the 6-month aP dose [GMR = 0·98, 95% credible interval (0·77 to 1·26); probability (GMR > 2/3) > 0·99; ITT analysis]. At 7 months old, the posterior median probability of quantitation for tetanus toxoid IgE was 0·22 (95% credible interval 0·12 to 0·34) in both the mixed schedule group and in the aP-only group. Despite exclusions, the results were consistent in the PP analysis. At 6 weeks old, irritability was the most common systemic solicited reaction reported in wP (65 [88%] of 74) versus aP (59 [82%] of 72) vaccinees. At the same age, severe systemic reactions were reported among 14 (19%) of 74 infants after wP and 8 (11%) of 72 infants after aP. There were 7 SAEs among 5 participants within the first 6 months of follow-up; on blinded assessment, none were deemed to be related to the study vaccines. Parental acceptance of mixed and aP-only schedules was high (71 [97%] of 73 versus 69 [96%] of 72 would agree to have the same schedule again). Conclusions: Compared to the aP-only schedule, the mixed schedule evoked noninferior PT-IgG responses, was associated with more severe reactions, but was well accepted by parents. Tetanus toxoid IgE responses did not differ across the study groups. Trial registration: Trial registered at the Australian and New Zealand Clinical 207 Trial Registry (ACTRN12617000065392p).
- Open Access
Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: a randomised, double-blind, non-inferiority trial
Summary: Background: In most high-income countries, infant vaccination with acellular pertussis (aP) vaccines is the standard of care for the prevention of pertussis disease. Based on immunological and epidemiological evidence, we hypothesised that substitution of the first aP dose in the vaccination schedule with whole-cell (wP) vaccine might protect against the development of IgE-mediated food allergy. Here we report the results of a randomised comparison of the reactogenicity, immunogenicity, and IgE-mediated immune responses of a mixed wP/aP primary schedule versus the standard aP-only schedule. Methods: OPTIMUM is a Bayesian, two-stage, double-blind, group sequential trial, enrolling healthy Australian-born infants. At approximately 6 weeks old, participants are randomly assigned (1:1) to a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB; Pentabio, PT Bio Farma, Indonesia) versus a hexavalent aP vaccine, which includes inactivated poliovirus vaccine (IPV) types 1, 2, and 3 in its formulation (DTaP-Hib-HepB-IPV; Infanrix Hexa, GlaxoSmithKline, Australia). All infants receive a hexavalent aP vaccine at 4 and 6 months old, as well as a tetravalent aP-based formulation at 18 months old (DTaP-IPV; Infanrix-IPV, GlaxoSmithKline, Australia) to ensure at least three doses of IPV as part of their childhood schedule while preserving blinding. In stage one, pertussis antigen-specific IgG responses were measured before and approximately one month after the 6-month aP vaccine doses. The immunogenicity of the mixed schedule (wP/aP/aP) was defined as being non-inferior to that of the aP-only schedule (aP/aP/aP) using a non-inferiority margin of 2/3 on the ratio of the geometric mean concentrations of pertussis toxin (PT) IgG approximately one month after the 6-month aP dose. Solicited adverse reactions were summarised by study arm and included all children who received the first dose of either wP or aP. Parental acceptance was assessed using a 5-point Likert scale. The trial is registered with ANZCTR (ACTRN12617000065392p). Results: Between March 7, 2018 and January 13, 2020, 150 infants were randomised (75 per arm). Demographic and baseline characteristics were balanced across the study arms. Most infants were born to aP-vaccinated mothers. In the intent-to-treat analysis, PT-IgG responses of the mixed schedule were non-inferior to the aP-only schedule approximately one month after a 6-month aP dose [geometric mean ratio (GMR) = 0·98, 95% Bayesian credible interval (0·77 to 1·26); probability (GMR > 2/3) > 0·99]. Severe solicited systemic adverse reactions were reported among 14 of 74 (19%) infants after a first dose of wP and among 8 of 72 (11%) infants after a first dose of aP; irritability after the first dose of pertussis-containing vaccine was the most frequent severe event (11 of 74 [15%] wP recipients versus 7 of 72 [10%] aP recipients). Within 6 months of enrolment, 7 serious adverse events were reported, with none deemed related to the study vaccines. Parental acceptance of the mixed schedule was high (97% would agree to have this schedule again). Interpretation: The mixed wP/aP schedule was associated with more reactions than the aP-only schedule, but these were mostly non-severe. The mixed schedule was well accepted by parents and evoked non-inferior PT-IgG responses after completion of the three-dose primary series. Funding: Telethon New Children’s Hospital Research Fund and National Health and Medicine Research Council. Research in context: We searched PubMed on April 17, 2023, for paediatric studies of heterologous priming with whole-cell pertussis (wP) vaccine and acellular pertussis (aP) vaccine, with no language or date restrictions. We used the terms [“whole-cell pertussis vaccine” AND “acellular pertussis vaccine”], OR [“IgE” AND “tetanus toxoid”]. Of the 997 articles retrieved, we found no published randomised comparisons between heterologous versus exclusive primary routine vaccination with either wP or aP-based formulations. In two observational studies, laboratory-confirmed pertussis disease was less common among school-aged children and adolescents who received wP versus aP as a first dose. A heterologous wP/aP primary schedule (in which the first dose was wP) was associated with lower rates of pertussis disease than an aP-only primary schedule. In a case-control study, pertussis was less common among children who had received mixed wP/three-component (3c)-aP vaccine (including pertussis toxoid, filamentous haemagglutinin, and pertactin) versus those exclusively primed with 3c-aP vaccine formulations. No evidence of a difference was observed among those vaccinated with a heterologous wP/five-component (5c)-aP primary schedule versus those exclusively primed with a 5c-aP vaccine formulation (including the above-mentioned pertussis antigens as well as fimbriae type 2 and 3). In contrast, another case-control study found that compared to the 5c-aP-only priming strategy, a primary series including one or more doses of a wP vaccine formulation, with reported efficacy against laboratory-confirmed pertussis between 36% (95% CI 14% to 52%) and 48% (95% 37% to 58%), was associated with higher vaccine effectiveness against pertussis disease more than a decade after priming. In none of the case-control analyses was the nature of the heterologous schedules further described. Two clinical and immunological studies reported that wP-only schedules were associated with lower post-priming tetanus toxoid (TT)-IgE concentrations than homologous priming with aP-containing vaccines. An additional study reported lower TT-IgE concentrations after a first dose of wP versus aP. Added value of this study: To our knowledge, this is the first trial to evaluate the immunogenicity, reactogenicity, and IgE-mediated immune responses to a mixed primary schedule consisting of a first dose of wP given at...
Open AccessImmunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: a randomised, double-blind, non-inferiority trial
Summary: Background: In most high-income countries, infant vaccination with acellular pertussis (aP) vaccines is the standard of care for the prevention of pertussis disease. Based on immunological and epidemiological evidence, we hypothesised that substitution of the first aP dose in the vaccination schedule with whole-cell (wP) vaccine might protect against the development of IgE-mediated food allergy. Here we report the results of a randomised comparison of the reactogenicity, immunogenicity, and IgE-mediated immune responses of a mixed wP/aP primary schedule versus the standard aP-only schedule. Methods: OPTIMUM is a Bayesian, two-stage, double-blind, group sequential trial, enrolling healthy Australian-born infants. At approximately 6 weeks old, participants are randomly assigned (1:1) to a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB; Pentabio, PT Bio Farma, Indonesia) versus a hexavalent aP vaccine, which includes inactivated poliovirus vaccine (IPV) types 1, 2, and 3 in its formulation (DTaP-Hib-HepB-IPV; Infanrix Hexa, GlaxoSmithKline, Australia). All infants receive a hexavalent aP vaccine at 4 and 6 months old, as well as a tetravalent aP-based formulation at 18 months old (DTaP-IPV; Infanrix-IPV, GlaxoSmithKline, Australia) to ensure at least three doses of IPV as part of their childhood schedule while preserving blinding. In stage one, pertussis antigen-specific IgG responses were measured before and approximately one month after the 6-month aP vaccine doses. The immunogenicity of the mixed schedule (wP/aP/aP) was defined as being non-inferior to that of the aP-only schedule (aP/aP/aP) using a non-inferiority margin of 2/3 on the ratio of the geometric mean concentrations of pertussis toxin (PT) IgG approximately one month after the 6-month aP dose. Solicited adverse reactions were summarised by study arm and included all children who received the first dose of either wP or aP. Parental acceptance was assessed using a 5-point Likert scale. The trial is registered with ANZCTR (ACTRN12617000065392p). Results: Between March 7, 2018 and January 13, 2020, 150 infants were randomised (75 per arm). Demographic and baseline characteristics were balanced across the study arms. Most infants were born to aP-vaccinated mothers. In the intent-to-treat analysis, PT-IgG responses of the mixed schedule were non-inferior to the aP-only schedule approximately one month after a 6-month aP dose [geometric mean ratio (GMR) = 0·98, 95% Bayesian credible interval (0·77 to 1·26); probability (GMR > 2/3) > 0·99]. Severe solicited systemic adverse reactions were reported among 14 of 74 (19%) infants after a first dose of wP and among 8 of 72 (11%) infants after a first dose of aP; irritability after the first dose of pertussis-containing vaccine was the most frequent severe event (11 of 74 [15%] wP recipients versus 7 of 72 [10%] aP recipients). Within 6 months of enrolment, 7 serious adverse events were reported, with none deemed related to the study vaccines. Parental acceptance of the mixed schedule was high (97% would agree to have this schedule again). Interpretation: The mixed wP/aP schedule was associated with more reactions than the aP-only schedule, but these were mostly non-severe. The mixed schedule was well accepted by parents and evoked non-inferior PT-IgG responses after completion of the three-dose primary series. Funding: Telethon New Children’s Hospital Research Fund and National Health and Medicine Research Council. Research in context: We searched PubMed on April 17, 2023, for paediatric studies of heterologous priming with whole-cell pertussis (wP) vaccine and acellular pertussis (aP) vaccine, with no language or date restrictions. We used the terms [“whole-cell pertussis vaccine” AND “acellular pertussis vaccine”], OR [“IgE” AND “tetanus toxoid”]. Of the 997 articles retrieved, we found no published randomised comparisons between heterologous versus exclusive primary routine vaccination with either wP or aP-based formulations. In two observational studies, laboratory-confirmed pertussis disease was less common among school-aged children and adolescents who received wP versus aP as a first dose. A heterologous wP/aP primary schedule (in which the first dose was wP) was associated with lower rates of pertussis disease than an aP-only primary schedule. In a case-control study, pertussis was less common among children who had received mixed wP/three-component (3c)-aP vaccine (including pertussis toxoid, filamentous haemagglutinin, and pertactin) versus those exclusively primed with 3c-aP vaccine formulations. No evidence of a difference was observed among those vaccinated with a heterologous wP/five-component (5c)-aP primary schedule versus those exclusively primed with a 5c-aP vaccine formulation (including the above-mentioned pertussis antigens as well as fimbriae type 2 and 3). In contrast, another case-control study found that compared to the 5c-aP-only priming strategy, a primary series including one or more doses of a wP vaccine formulation, with reported efficacy against laboratory-confirmed pertussis between 36% (95% CI 14% to 52%) and 48% (95% 37% to 58%), was associated with higher vaccine effectiveness against pertussis disease more than a decade after priming. In none of the case-control analyses was the nature of the heterologous schedules further described. Two clinical and immunological studies reported that wP-only schedules were associated with lower post-priming tetanus toxoid (TT)-IgE concentrations than homologous priming with aP-containing vaccines. An additional study reported lower TT-IgE concentrations after a first dose of wP versus aP. Added value of this study: To our knowledge, this is the first trial to evaluate the immunogenicity, reactogenicity, and IgE-mediated immune responses to a mixed primary schedule consisting of a first dose of wP given at...
- 28 February 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of nafamostat and camostat mesylate randomised clinical trials
Review question / Objective: The primary objective of the systematic review and meta-analysis is to determine whether TMPRSS2 inhibition with nafamostat or camostat mesylate is associated with a reduced risk of 30-day all-cause mortality in hospitalised and non-hospitalised adults with COVID-19. Condition being studied: Coronavirus disease 2019 (COVID-19). COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age.
- 28 February 2023
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of nafamostat and camostat mesylate randomised clinical trials
Review question / Objective: The primary objective of the systematic review and meta-analysis is to determine whether TMPRSS2 inhibition with nafamostat or camostat mesylate is associated with a reduced risk of 30-day all-cause mortality in hospitalised and non-hospitalised adults with COVID-19. Condition being studied: Coronavirus disease 2019 (COVID-19). COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age.